Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its ...

Benefit claimants, whistleblowers and welfare experts working on the frontline offer Labour ministers alternatives to cuts ...

The following is a summary of “Neurofilament heavy chain in secondary progressive multiple sclerosis,” published in the January 2025 issue of Neurology by Angelis et al. Biomarkers are essential for ...

The onset of multiple sclerosis (MS) in older individuals correlates with a higher risk of developing primary progressive MS, faster progression to secondary progressive MS, and increased disability ...

most people have relapsing-remitting MS. Other types include primary progressive MS, secondary progressive MS, and clinically isolated MS. Contact your doctor if you have concerns about MS. They ...

“We are excited to announce this breakthrough in understanding how nasal foralumab induces immune modulation in Secondary Progressive MS patients,” said Dr. Tanuja Chitnis, M.D., Principal ...

RRMS may also progress to secondary progressive MS. SPMS follows an initial pattern of relapses and remissions and then gets progressively worse. RRMS can eventually transition to SPMS.

WHEN life gave Lina Nielsen lemons, she sprinted straight to the Olympics.  The 28-year-old was diagnosed with multiple sclerosis at 17 years old, leaving her terrified of disability. Doctors gave ...

"With no treatment options currently available for the broad population of patients with secondary progressive multiple sclerosis, tolebrutinib has demonstrated its ability to delay disability by ...

There isn’t enough evidence to back the use of Novartis Mayzent for secondary progressive multiple sclerosis on the NHS (SPMS), despite a desperate lack of treatments for this form of the ...